New insights in Chagas' disease treatment

Drugs of the Future

Volumn 35, Issue 5, 2010, Pages 409-419

  Urbina, Julio A ^a  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; 2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; 24,25 EPIMINOLANOSTEROL; ALBACONAZOLE; AMIODARONE; ANTIPROTOZOAL AGENT; AZACOSTEROL; BENZNIDAZOLE; CRA 3316; CYSTEINE PROTEINASE INHIBITOR; ERGOSTEROL; ITRACONAZOLE; K 777; KETOCONAZOLE; LYSOPHOSPHOLIPID; MEVINOLIN; NIFURTIMOX; POSACONAZOLE; RAVUCONAZOLE; STEROL DERIVATIVE; TERBINAFINE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ALLERGIC DERMOPATHY; ANOREXIA; ANTIPROTOZOAL ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW DEPRESSION; CHAGAS DISEASE; CLINICAL FEATURE; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; IRRITABILITY; NAUSEA AND VOMITING; NONHUMAN; PARESTHESIA; PATHOGENESIS; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIC PURPURA; TRYPANOSOMA CRUZI; WEIGHT REDUCTION;

EID: 77955436769     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.05.1484391     Document Type: Article

References (125)

1. Chagas, C. Novo entidade morbida do homen. Resumo greal dos estudos etiologicos e clínicos. Mem Inst Oswaldo Cruz 1911, 3: 219-75.
2. Aufderheide, A.C., Sato, W., Madden, M. et al. A 9,000-year record of Chagas' disease. Proc Natl Acad Sci U S A 2004, 101(7): 2034-9.
3. Hotez, P.J., Bottazzi, M.E., Franco-Paredes, C., Ault, S.K., Periago, M.R. The neglected tropical diseases of Latin America and the Caribbean: A review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis 2008, 2(9): e300.
4. Schofield, C.J., Jannin, J., Salvatella, R. The future of Chagas disease control. Trends Parasitol 2006, 22(12): 583-8.
5. Tarleton, R.L., Reithinger, R., Urbina, J.A., Kitron, U. Gurtler, R.E. The challenges of Chagas Disease - Grim outlook or glimmer of hope. PLoS Med 2007, 4(12): e332.
6. Gurtler, R.E., Diotaiuti, L., Kitron, U. Commentary: Chagas disease: 100 years since discovery and lessons for the future. Int J Epidemiol 2008, 37(4): 698-701.
7. Pinto Dias, J.C. Epidemiologia. In: Trypanosoma Cruzi e Doença de Chagas, 2 Ed. Z. Brener, Z. Andrade, C. Barral-Netto (Eds.). Guanabara Koogan: Rio de Janeiro, 1999, 48-74.
8. Bern, C., Montgomery, S.P., Herwaldt, B.L. et al. Evaluation and treatment of Chagas disease in the United States: A systematic review. JAMA 2007, 298(18): 2171-81.
9. Diaz, J.H. Chagas disease in the United States: A cause for concern in Louisiana? J La State Med Soc 2007, 159(1): 21-3, 5-9.
10. Piron, M., Verges, M., Munoz, J. et al. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion 2008, 48(9): 1862-8.
11. Gascon, J., Albajar, P., Canas, E. et al. [Diagnosis, management and treatment of chronic Chagas' heart disease in areas where Trypanosoma cruzi infection is not endemic]. Rev Esp Cardiol 2007, 60(3): 285-93.
12. Reithinger, R., Tarleton, R.L., Urbina, J.A., Kitron, U., Gurtler, R.E. Eliminating Chagas disease: Challenges and a roadmap. BMJ 2009, 338: 1044-6.
13. Dias, J.C., Silveira, A.C., Schofield, C.J. The impact of Chagas disease control in Latin America: A review. Mem Inst Oswaldo Cruz 2002, 97(5): 603-12.
14. Franco-Paredes, C., Bottazzi, M.E., Hotez, P.J. The unfinished public health agenda of Chagas disease in the era of globalization. PLoS Negl Trop Dis 2009, 3(7): e470.
15. Alarcon de Noya, B., Diaz-Bello, Z. Cotmenares, C. et al. Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela. J Infect Dis 2010, 201(9): 1308-15.
16. Pinto, A.Y., Ferreira, A.G. Jr., Valente, V.D., Harada, G.S., Valente, S.A. Urban outbreak of acute Chagas disease in Amazon region of Brazil: Four-year follow-up after treatment with benznidazole. Rev Panam Salud Publica 2009, 25(1): 77-83.
17. Benchimol-Barbosa, P.R. Trends on acute Chagas' disease transmitted by oral route in Brazil: Steady increase in new cases and a concealed residual fluctuation. Int J Cardiol 2009, Epub ahead of print.
18. Tekiel, V., Alba-Soto, C.D., Gonzalez Cappa, S.M., Postan, M., Sanchez, D.O. Identification of novel vaccine candidates for Chagas' disease by immunization with sequential fractions of a trypomastigote cDNA expression library. Vaccine 2009, 27(9): 1323-32.
19. Urbina, J.A. New advances in the management of a long-neglected disease. Clin Infect Dis 2009, 49(11): 1685-7.
20. Ribeiro, I., Sevcsik, A.M., Alves, F. et al. New, improved treatments for chagas disease: From the r&d pipeline to the patients. PLoS Negl Trap Dis 2009, 3(7): e484.
21. Gutierrez, F.R., Guedes, P.M., Gazzinelli, R.T., Silva, J.S. The role of parasite persistence in pathogenesis of Chagas heart disease. Parasite Immunol 2009, 31(11): 673-85.
22. Brener, Z., Gazzinelli, R.T. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int Arch Allergy Immunol 1997, 114(2): 103-10.
23. Padilla, A.M., Bustamante, J.M., Tarleton, R.L. CD8+ T cells in Trypanosoma cruzi infection. Curr Opin Immunol 2009, 21(4): 385-90.
24. Marin-Neto, J.A., Cunha-Neto, E., Maciel, B.C., Simoes, M.V. Pathogenesis of chronic Chagas heart disease. Circulation 2007, 115(9): 1109-23.
25. Albareda, M.C., Laucella, S.A., Alvarez, M.G., Armenti, A.H., Bertochi, G., Tarleton, R.L., Postan, M. Trypanosoma cruzi modulates the profile of memory CD8+ T cells in chronic Chagas' disease patients. Int Immunol 2006, 18(3): 465-71.
26. Rassi, A., Jr., Dias, J.C., Marin-Neto, J.A., Rassi, A. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas disease. Heart 2009, 95: 524-34.
27. Rassi, A., Jr., Rassi, A., Little, W.C. Chagas' heart disease. Clin Cardiol 2000, 23(12): 883-9.
28. Cançado, J.R. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trap Sao Paulo 2002, 44(1): 29-37.
29. Cançado, J.R. Criteria of Chagas disease cure. Mem Inst Oswaldo Cruz 1999, 94 (Suppl. 1): 331-6.
30. Rassi, A., Jr., Dias, J.C., Marin-Neto, J.A., Rassi, A. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease. Heart 2009, 95(7): 524-34.
31. Kirchhoff, L.V. Chagas' disease (American trypanosomiasis): A Tropical disease now emerging in the United States. In: Emerging Infections, 3rd Ed. W.M. Scheid, W.A. Craig, J.M. Hughes (Eds.). ASM Press Washington, D.C., 1999, 111-34.
32. Filardi, L.S., Brener, Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg 1987, 81(5): 755-9.
33. Murta, S.M., Gazzinelli, R.T., Brener, Z., Romanha, A.J. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol Biochem Parasitol 1998, 93(2): 203-14.
34. Romanha, A.J., Alves, R.O., Murta, S.M., Silva, J.S., Ropert, C., Gazzinelli, R.T. Experimental chemotherapy against Trypanosoma cruzi infection: Essential role of endogenous interferon-gamma in mediating parasitologic cure. J Infect Dis 2002, 186(6): 823-8.
35. Bahia-Oliveira, L.M., Gomes, J.A., Cancado, J.R. et al. Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago. J Infect Dis 2000, 182(2): 634-8.
36. Andrade, A.L., Martelli, C.M., Oliveira, R.M. et al. Short report: Benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am J Trop Med Hyg 2004, 71(5): 594-7.
37. de Andrade, A.L., Zicker, F., de Oliveira, R.M. et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996, 348(9039): 1407-13.
38. Sosa-Estani, S., Segura, E.L. Etiological treatment in patients infected by Trypanosoma cruzi: Experiences in Argentina. Curr Opin Infect Dis 2006, 19(6): 583-7.
39. Silveira, C.A., Castillo, E., Castro, C. [Evaluation of an specific treatment for Trypanosoma cruzi in children, in the evolution of the indeterminate phase]. Rev Soc Bras Med Trap 2000, 33(2): 191-6.
40. Solari, A., Ortiz, S., Soto, A. et al. Treatment of Trypanosoma cruzi-infected children with nifurtimox: A 3 year follow-up by PCR. J Antimicrob Chemother 2001, 48(4): 515-9.
41. Yun, O., Lima, M.A., Ellman, T. et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins sans Frontieres. PLoS Negl Trop Dis 2009, 3(7): e488.
42. Martins, H.R., Figueiredo, L.M., Valamiel-Silva, J.C. et al. Persistence of PCR-positive tissue in benznidazole-treated mice with negative blood parasitological and serological tests in dual infections with Trypanosoma cruzi stocks from different genotypes. J Antimicrob Chemother 2008, 61(6): 1319-27.
43. Anez, N., Carrasco, H., Parada, H. et al. Myocardial parasite persistence in chronic chagasic patients. Am J Trap Med Hyg 1999, 60(5): 726-32.
44. Britto, C., Silveira, C., Cardoso, M.A., Marques, P., Luquetti, A., Macedo, V., Fernandes, O. Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction. Mem Inst Oswaldo Cruz 2001, 96(6): 823-6.
45. Braga, M.S., Lauria-Pires, L., Arganaraz, E.R., Nascimento, R.J., Teixeira, A.R. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop Sao Paulo 2000, 42(3): 157-61.
46. Lauria-Pires, L., Braga, M.S., Vexenat, A.C., Nitz, N., Simoes-Barbosa, A., Tinoco, D.L., Teixeira, A.R. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg 2000, 63(3-4): 111-8.
47. Garcia, S., Ramos, C.O., Senra, J.F. et al. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 2005, 49(4): 1521-8.
48. Fernandes, C.D., Tiecher, F.M., Balbinot, M.M., Liarte, D.B., Scholl, D., Steindel, M., Romanha, A. Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do SuI evaluated during a three years follow-up. Mem Inst Oswaldo Cruz 2009, 104(1): 27-32.
49. Krautz, G.M., Kissinger, J.C., Krettli, A.U. The targets of the lytic antibody response against Trypanosoma cruzi. Parasitol Today 2000, 16(1): 31-4.
50. Krautz, G.M., Galvao, L.M., Cancado, J.R., Guevara-Espinoza, A., Ouaissi, A., Krettli, A.U. Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease. J Clin Microbiol 1995, 33(8): 2086-90.
51. Pereira-Chioccola, V.L., Fragata-Filho, A.A., Levy, A.M., Rodrigues, M.M., Schenkman, S. Enzyme-linked immunoassay using recombinant transsialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment. Clin Diagn Lab Immunol 2003, 10(5): 826-30.
52. Urbina, J.A., Docampo, R. Specific chemotherapy of Chagas disease: Controversies and advances. Trends Parasitol 2003, 19(11): 495-501.
53. Buckner, F.S. Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. Adv Exp Med Biol 2008, 625: 61-80.
54. Viotti, R., Vigliano, C. Etiological treatment of chronic Chagas disease: Neglected 'evidence' by evidence-based medicine. Expert Rev Anti Infect Ther 2007, 5(4): 717-26.
55. Viotti, R., Vigtiano, C., Lococo, B. et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: A nonrandomized trial. Ann Intern Med 2006, 144(10): 724-34.
56. Urbina, J.A. Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Trop 2009, 115(1-2): 55-68.
57. Docampo, R. Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem Biol Interact 1990, 73(1): 1-27.
58. Kalil, J., Cunha-Neto, E. Autoimmunity in Chagas disease cardiomyopathy: Fullfilling the criteria at last? ParasitolToday 1996, 12: 396-9.
59. Cunha-Neto, E., Duranti, M., Gruber, A. et al. Autoinmunity in Chagas disease cardiopathy: Biological relevance of a cardiac myosin-specific epitope crossreactive to an inmunodominant Trypanosoma cruzi antigen. Proc Natl Acad Sci U S A 1995, 92(8): 3541-5.
60. Urbina, J.A. Parasitological cure of Chagas disease: Is it possible? Is it Relevant? Mem Inst Oswaldo Cruz 1999, 94(Suppl. 1): 349-55.
61. Croft, S.L., Barrett, M.P., Urbina, J.A. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 2005, 21(11): 508-12.
62. Tarleton, R.L. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 2001, 31(5-6): 550-4.
63. Apt, W., Heitmann, I., Jercic, L. et al. [Tratamiento antiparasitario de la enfremedad de Chagas]. Rev Chil Infect 2008, 25(5): 384-9.
64. Marin-Neto, J.A., Rassi, A. Jr., Morillo, C.A. et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008, 156(1): 37-43.
65. Pinto Dias, J.C. The treatment of Chagas disease (South American trypanosomiasis). Ann Intern Med 2006, 144(10): 772-4.
66. Gomes, Y.M., Lorena, V.M., Luquetti, A.O. Diagnosis of Chagas disease: What has been achieved? What remains to be done with regard to diagnosis and follow up studies? Mem Inst Oswaldo Cruz 2009, 104(4): 115-21.
67. Britto, C., Cardoso, M.A., Marques, P., Fernandes, O., Morel, C.M. Polymerase chain reaction detection: New insights into the diagnosis of chronic Chagas disease. Mem Inst Oswaldo Cruz 1999, 94(Suppl. 1): 305-6.
68. Britto, C., Cardoso, M.A., Vanni, C.M. et al. Polymerase chain reaction detection of Trypanosoma cruzi in human blood samples as a tool for diagnosis and treatment evaluation. Parasitology 1995, 110(Pt. 3): 241-7.
69. Benvenuti, L.A., Roggerio, A., Freitas, H.F., Mansur, A.J., Fiorelli, A., Higuchi, M.L.. Chronic American trypanosomiasis: Parasite persistence in endomyocardial biopsies is associated with high-grade myocarditis. Ann Trap Med Parasitot 2008, 102(6): 481-7.
70. Coronado, X., Zulntay, I., Reyes, E. et al. Comparison of Trypanosoma cruzi detection by PCR in blood and dejections of Triatoma infestans fed on patients with chronic Chagas disease. Acta Trap 2006, 98(3): 314-7.
71. Castro, A.M., Luquetti, A.O., Rassi, A., Rassi, G.G., Chiari, E., Galvao, L.M. Blood culture and polymerase chain reaction for the diagnosis of the chronic phase of human infection with Trypanosoma cruzi. Parasitol Res 2002, 88(10): 894-900.
72. Bustamante, J.M., Bixby, L.M., Tarleton, R.L. Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med 2008, 14(5): 542-50.
73. Laucella, S.A., Mazliah, D.P., Bertocchi, G. et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: Surrogate markers of treatment efficacy. Clin Infect Dis 2009, 49(11): 1675-84.
74. Cooley, G., Etheridge, R.D., Boehlke, C. et al. High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl Trop Dis 2008, 2(10): e316.
75. Soeiro, M.N., de Castro, S.L. Trypanosoma cruzi targets for new chemotherapeutic approaches. Expert Opin Ther Targets 2009, 13(1): 105-21.
76. Urbina, J.A. Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz 2009, 104(Suppl. 1): 311-8.
77. Moton, A., Krishna, G., Wang, Z. Tolerability and safety profile of posaconazole: Evaluation of 18 controlled studies in healthy volunteers. J Clin Pharm Ther 2009, 34(3): 301-11.
78. Vazquez, J.A., Skiest, D.J., Tissot-Dupont, H., Lennox, J.L., Boparai, N., Isaacs, R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin Trials 2007, 8(2): 86-97.
79. Ullmann, A.J., Comely, O.A., Burchardt, A. et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006, 50(2): 658-66.
80. Silva, D.T., de Meirelles Mde, N., Almeida, D., Urbina, J.A., Pereira, M.C. Cytoskeleton reassembly in cardiomyocytes infected by Trypanosoma cruzi is triggered by treatment with ergosterol biosynthesis inhibitors. Int J Antimicrob Agents 2006, 27(6): 530-7.
81. Ferraz, M.L., Gazzinelli, R.T., Alves, R.O., Urbina, J.A., Romanha, A.J. Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. Antimicrob Agents Chemother 2009, 53(1): 174-9.
82. Ferraz, M.L., Gazzinelli, R.T., Alves, R.O., Urbina, J.A., Romanha, A.J. The anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. Antimicrob Agents Chemother 2007, 51(4): 1359-64.
83. Olivieri, B.P., Molina, J., de Castro, S.L., Pereira, M., Calvet, C.M., Urbina, J.A., Araujo-Jorge, T.C. A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. Int J Anticrob Agents 2010, 36(1): 79-83.
84. Pinazo, M.J., Espinosa, G., Gallego, M., Lopez-Chejade, P., Urbina, J.A., Gascon, J. Successful treatment with posaconazole of patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg 2010, 82(4): 583-7.
85. Urbina, J.A., Payares, G., Sanoja, C., Lira, R., Romanha, A.J. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int J Antimicrob Agents 2003, 21(1): 27-38.
86. Diniz, L.F., Caldas, I.S., Guedes, P.M. et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother 2010, Epub ahead of print.
87. Pasqualotto, A.C., Denning, D.W. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008, 61(Suppl. 1): i19-30.
88. Urbina, J.A., Payares, G., Sanoja, C., Molina, J., Lira, R., Brener, Z., Romanha, A.J. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int J Antimicrob Agents 2003, 21(1): 39-48.
89. Corrales, M., Cardozo, R., Segura, M.A., Urbina, J.A., Basombrio, M.A. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Antimicrob Agents Chemother 2005, 49(4): 1556-60.
90. Hucke, O., Gelb, M.H., Verlinde, C.L., Buckner, F.S. The protein farnesyl-transferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem 2005, 48(17): 5415-8.
91. Buckner, F., Yokoyama, K., Lockman, J. et al. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc Natl Acad Sci U S A 2003, 100(25): 15149-53.
92. Kraus, J.M., Verlinde, C.L., Karimi, M. Lepesheva, G.I., Gelb, M.H., Buckner, F.S. Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem 2009, 52(6): 1639-47.
93. Suryadevara, P.K., Olepu, S., Lockman, J.W. et al. Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. J Med Chem 2009, 52(12): 3703-15.
94. Chen, C.K., Doyle, P.S., Yermalitskaya, L.V., Mackey, Z.B., Ang, K.K., McKerrow, J.H., Podust, L.M. Trypanosoma cruzi CYP51 inhibitor Derived from a Mycobacterium tuberculosis screen hit. PLoS Negl Trap Dis 2009, 3(2): e372.
95. Doyle, P.S., Chen, C.K., Johnston, J.B. et al. A nonazole CYP51 inhibitor cures Chagas disease in a mouse model of acute infection. Antimicrob Agents Chemother 2010, 54(6): 2480-8.
96. Lepesheva, G.I., Park, H.W., Hargrove, T.Y. et al. Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections. J Biol Chem 2010, 285(3): 1773-80.
97. Rosenbaum, M.B., Chiale, P.A., Haedo, A., Lazzari, J.O., Elizari, M.V. Ten years of experience with amiodarone. Am Heart J 1983, 106(4 Pt. 2): 957-64.
98. Benaim, G., Sanders, J.M., Garcia-Marchan, Y. et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem 2006, 49(3): 892-9.
99. Paniz-Mondolfi, A.E., Perez-Alvarez, A.M., Lanza, G., Marquez, E., Concepcion, J.L. Amiodarone and itraconazole: A rational therapeutic approach for the treatment of chronic Chagas' disease. Chemotherapy 2009, 55(4): 228-33.
100. Serrano-Martin, X., Payares, G., De Lucca, M., Martinez, J.C., Mendoza-Leon, A., Benaim, G. Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrob Agents Chemother 2009, 53(12): 5108-13.
101. Serrano-Martin, X., Garcia-Marchan, Y., Fernandez, A., Rodriguez, N., Rojas, H., Visbal, G., Benaim, G. Amiodarone destabilizes intracellular Ca2+ homeostasis and biosynthesis of sterols in Leishmania mexicana. Antimicrob Agents Chemother 2009, 53(4): 1403-10.
102. Paniz-Mondolfi, A.E., Perez-Alvarez, A.M., Reyes-Jaimes, O., Socorro, G., Zerpa, O., Slova, D., Concepcion, J.L. Concurrent Chagas' disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug. Ther Clin Risk Manag 2008, 4(3): 659-63.
103. Cazzulo, J.J. Proteinases of Trypanosoma cruzi: Potential targets for the chemotherapy of Changas desease. Curr Top Med Chem 2002, 2(11): 1261-71.
104. Engel, J.C., Doyle, P.S., Hsieh, I., McKerrow, J.H. Cysteine protease inhibitors cure experimental Trypanosma cruzi infection. J Exp Med 1998, 188: 725-34.
105. Barr, S.C., Warner, K.L., Kornreic, B.G., Piscitelli, J., Wolfe, A., Benet, L., McKerrow, J.H. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother 2005, 49(12): 5160-1.
106. Doyle, P.S., Zhou, Y.M., Engel, J.C., McKerrow, J.H. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection. Antimicrob Agents Chemother 2007, 51(11): 3932-9.
107. McKerrow, J.H., Doyle, P.S., Engel, J.C. et al. Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz 2009, 104(Suppl. 1): 263-9.
108. Brak, K., Doyle, P.S., McKerrow, J.H., Ellman, J.A. Identification of a new class of nonpeptidic inhibitors of cruzain. J Am Chem Soc 2008, 130(20): 6404-10.
109. Caffrey, C.R., Schanz, M., Nkemgu-Njinkeng, J. et al. Screening of acyl hydrazide proteinase inhibitors for antiparasitic activity against Trypanosoma brucei. Int J Antimicrob Agents 2002, 19(3): 227-31.
110. Du, X., Guo, C., Hansell, E. et al. Synthesis and structure-activity relationship study of potent trypanocidal thiosemicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J Med Chem 2002, 45(13): 2695-707.
111. Brak, K., Kerr, I.D., Barrett, K.T. et al. Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy. J Med Chem 2010, 53(4): 1763-73.
112. Chen, Y.T., Lira, R., Hansell, E., McKerrow, J.H., Roush, W.R. Synthesis of macrocyclic trypanosomal cysteine protease inhibitors. Bioorg Med Chem Lett 2008, 18(22): 5860-3.
113. Guido, R.V., Trossini, G.H., Castilho, M.S., Oliva, G., Ferreira, E.I., Andricopulo, A.D. Structure-activity relationships for a class of selective inhibitors of the major cysteine protease from Trypanosoma cruzi. J Enzyme Inhib Med Chem 2008, 23(6): 964-73.
114. Urbina, J.A. Chemotherapy of Chagas' disease: The how and the why. J Mol Med 1999, 77(3): 332-8.
115. Lazardi, K., Urbina, J.A., de Souza, W. Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafme, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 1990, 34(11): 2097-105.
116. Urbina, J.A., Lazardi, K., Aguirre, T., Piras, M.M., Piras, R. Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 1988, 32(8): 1237-42.
117. Urbina, J.A., Lazardi, K., Marchan, E. et al. Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 1993, 37(3): 580-91.
118. Urbina, J.A., Vivas, J., Lazardi, K., Molina, J., Payares, G., Piras, M.M., Piras, R. Antiproliferative effects of delta 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: In vitro and in vivo studies. Chemotherapy 1996, 42(4): 294-307.
119. Araujo, M.S., Martins-Filho, O.A., Pereira, M.E., Brener, Z. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. J Antimicrob Chemother 2000, 45(6): 819-24.
120. Charlton-Menys, V., Durrington, P.N. Squalene synthase inhibitors: Clinical pharmacology and cholesterol-lowering potential. Drugs 2007, 67(1): 11-6.
121. Davidson, M.H. Squalene synthase inhibition: A novel target for the management of dyslipidemia. Curr Atheroscler Rep 2007, 9(1): 78-80.
122. Burnett, J.R. Drug evaluation: TAK-475 - An oral inhibitor of squalene synthase for hyperlipidemia. Curr Opin Investig Drugs 2006, 7(9): 850-6.
123. Urbina, J.A., Concepcion, J.L., Caldera, A., Payares, G., Sanoja, C., Otomo, T., Hiyoshi, H. In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob Agents Chemother 2004, 48(7): 2379-87.
124. Bahia, M.T., Talvani, A., Chang, S., Ribeiro, I. Combination of benznidazole and nifurtimox plus posaconazole enhances the activity against Trypanosoma cruzi in experimental Chagas disease. Am J Trop Med Hyg [58th Annu Med Am Soc Trop Med Hyg (Nov 18-22, Washington) 2009] 2009, Abst 747.
125. Danzon, P.M. At what price? Nature 2007, 449(159): 176-9.